Acute-Phase Serum Amyloid A Regulates Tumor Necrosis Factor α and Matrix Turnover and Predicts Disease Progression in Patients With Inflammatory Arthritis Before and After Biologic Therapy

被引:97
作者
Connolly, Mary [2 ]
Mullan, Ronan H. [2 ]
McCormick, Jennifer [2 ]
Matthews, Clare [2 ]
Sullivan, Owen [2 ]
Kennedy, Aisling [2 ]
FitzGerald, Oliver [2 ]
Poole, A. Robin [3 ,4 ]
Bresnihan, Barry
Veale, Douglas J. [2 ]
Fearon, Ursula [1 ,2 ]
机构
[1] St Vincents Univ Hosp, Dept Rheumatol, Dublin Acad Med Ctr, Dublin 4, Ireland
[2] Conway Inst Biomol & Biomed Res, Dublin, Ireland
[3] McGill Univ, Montreal, PQ, Canada
[4] Shriners Hosp Children, Montreal, PQ, Canada
来源
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 04期
基金
爱尔兰科学基金会;
关键词
FORMYL PEPTIDE RECEPTOR-LIKE-1; EARLY RHEUMATOID-ARTHRITIS; II COLLAGEN; PSORIATIC-ARTHRITIS; SYNOVIAL TISSUE; JOINT DAMAGE; RADIOGRAPHIC PROGRESSION; CARTILAGE DEGRADATION; LOCAL EXPRESSION; DOUBLE-BLIND;
D O I
10.1002/art.33455
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective. To investigate the relationship between acute-phase serum amyloid A (A-SAA) and joint destruction in inflammatory arthritis. Methods. Serum A-SAA and C-reactive protein (CRP) levels, the erythrocyte sedimentation rate (ESR), and levels of matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, MMP-13, tissue inhibitor of metalloproteinases 1 (TIMP-1), vascular endothelial growth factor (VEGF), and type I and type II collagen-generated biomarkers C2C and C1,2C were measured at 0-3 months in patients with inflammatory arthritis commencing anti-tumor necrosis factor alpha (anti-TNF alpha) therapy and were correlated with 1-year radiographic progression. The effects of A-SAA on MMP/TIMP expression on RA fibroblast-like synoviocytes (FLS), primary human chondrocytes, and RA/psoriatic arthritis synovial explant cultures were assessed using real-time polymerase chain reaction, enzyme-linked immunosorbent assay, antibody protein arrays, and gelatin zymography. Results. Serum A-SAA levels were significantly (P < 0.05) correlated with MMP-3, the MMP-3: TIMP-1 ratio, C1,2C, C2C, and VEGF. The baseline A-SAA level but not the ESR or the CRP level correlated with the 28-joint swollen joint count and was independently associated with 1-year radiographic progression (P = 0.038). A-SAA increased MMP-1, MMP-3, MMP-13, and MMP/TIMP expression in RA FLS and synovial explants (P < 0.05). In chondrocytes, A-SAA induced MMP-1, MMP-3, and MMP-13 messenger RNA and protein expression (all P < 0.01), resulting in a significant shift in MMP:TIMP ratios (P < 0.05). Gelatin zymography revealed that A-SAA induced MMP-2 and MMP-9 activity. Blockade of the A-SAA receptor SR-B1 (A-SAA receptor scavenger receptor-class B type 1) inhibited MMP-3, MMP-2, and MMP-9 expression in synovial explant cultures ex vivo. Importantly, we demonstrated that A-SAA has the ability to induce TNF alpha expression in RA synovial explant cultures (P < 0.05). Conclusion. A-SAA may be involved in joint destruction though MMP induction and collagen cleavage in vivo. The ability of A-SAA to regulate TNF alpha suggests that A-SAA signaling pathways may provide new therapeutic strategies for the treatment of inflammatory arthritis.
引用
收藏
页码:1035 / 1045
页数:11
相关论文
共 53 条
[1]
THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]
Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line [J].
Artl, A ;
Marsche, G ;
Pussinen, P ;
Knipping, G ;
Sattler, W ;
Malle, E .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2002, 34 (04) :370-381
[3]
Serum amyloid a binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases [J].
Baranova, IN ;
Vishnyakova, TG ;
Bocharov, AV ;
Kurlander, R ;
Chen, ZG ;
Kimelman, ML ;
Remaley, AT ;
Csako, G ;
Thomas, F ;
Eggerman, TL ;
Patterson, AP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (09) :8031-8040
[4]
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[5]
THE ACUTE-PHASE RESPONSE [J].
BAUMANN, H ;
GAULDIE, J .
IMMUNOLOGY TODAY, 1994, 15 (02) :74-80
[6]
Effect of diet on fat cell size and hormone-sensitive lipase activity [J].
Berger, JJ ;
Barnard, RJ .
JOURNAL OF APPLIED PHYSIOLOGY, 1999, 87 (01) :227-232
[7]
Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1 [J].
Bjoerkman, Lena ;
Karlsson, Jennie ;
Karlsson, Anna ;
Rabiet, Marie-Josephe ;
Boulay, Francois ;
Fu, Huamei ;
Bylund, Johan ;
Dahlgren, Claes .
JOURNAL OF LEUKOCYTE BIOLOGY, 2008, 83 (02) :245-253
[8]
The Proinflammatory Activity of Recombinant Serum Amyloid A Is Not Shared by the Endogenous Protein in the Circulation [J].
Bjorkman, Lena ;
Raynes, John G. ;
Shah, Chandrabala ;
Karlsson, Anna ;
Dahlgren, Claes ;
Bylund, Johan .
ARTHRITIS AND RHEUMATISM, 2010, 62 (06) :1660-1665
[9]
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[10]
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change [J].
Bruynesteyn, K ;
Boers, M ;
Kostense, P ;
van der Linden, S ;
van der Heijde, D .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :179-182